HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BARBEAU, A. Articles by ROY, M. Search for Related Content PubMed PubMed Citation Articles by BARBEAU, A. Articles by ROY, M.

Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease

From the Department of Neurobiology, Clinical Research Institute of Montreal; the Department of Medicine, University of Montreal and Hôtel-Dieu Hospital, Montreal.

Benzerazide (Ro 4-4602), was studied over a 75-month period of observation in 132 patients with Parkinson's disease. The combined therapeutic approach was without biological toxicity, was well tolerated by 95 percent of patients, and was highly effective: 72 percent of patients improved by more than 50 percent on a functional activity scale and the group as a whole improved on an objective battery by a mean of 46 percent. Neurologic side effects of abnormal involuntary movements, falls, and oscillations in performance were not improved over levodopa used alone. The combined therapy is to be preferred over the use of levodopa alone in the symptomatic management of Parkinson's disease.

Requests for reprints should be addressed to Dr. Barbeau, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada.

This study was supported in part by Hoffmann-La Roche Company, the Medical Research Council of Canada (MT-4938), the W. Garfield Weston Foundation and the United Parkinson's Disease Foundation.

Received for publication August 4, 1975.

This article has been cited by other articles:

				T. Ozawa, D. Paviour, N. P. Quinn, K. A. Josephs, H. Sangha, L. Kilford, D. G. Healy, N. W. Wood, A. J. Lees, J. L. Holton, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations Brain, December 1, 2004; 127(12): 2657 - 2671. [Abstract] [Full Text] [PDF]

				B.-P. Bejjani, D. Gervais, I. Arnulf, S. Papadopoulos, S. Demeret, A.-M. Bonnet, P. Cornu, P. Damier, and Y. Agid Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation J. Neurol. Neurosurg. Psychiatry, May 1, 2000; 68(5): 595 - 600. [Abstract] [Full Text]

				W. C. Koller, J. T. Hutton, E. Tolosa, and R. Capilldeo Immediate-release and controlled-release carbidopa/levodopa in PD : A 5-year randomized multicenter study Neurology, September 1, 1999; 53(5): 1012 - 1012. [Abstract] [Full Text] [PDF]